Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(6/week)
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Guatemala
(0/week)
View all
(6/week)
News
United States
(507/week)
Manufacturing
(335/week)
Energy
(278/week)
Technology
(347/week)
Other Energy
(240/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Bicalutamide
May 29, 2020
Final PROSPER Results Show XTANDI® (enzalutamide) Significantly Extends Overall Survival in Men with Non-Metastatic Castration-Resistant Prostate Cancer
May 29, 2020
XTANDI® (enzalutamide) Approved by Japan MHLW for the Treatment of Prostate Cancer with Distant Metastasis
Feb 11, 2020
XTANDI® (enzalutamide) Demonstrates Significant Improvement in Overall Survival in Phase 3 PROSPER Trial of Patients with nmCRPC
Dec 16, 2019
XTANDI® (enzalutamide) Approved by U.S. FDA for the Treatment of Metastatic Castration-Sensitive Prostate Cancer
Aug 21, 2019
U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review for the Treatment of Men with Metastatic Hormone-Sensitive Prostate Cancer
Apr 29, 2019
U.S. FDA accepts New Drug Application and grants Priority Review for darolutamide
Mar 28, 2019
ESSA Pharma Announces Nomination of EPI-7386 as Lead Clinical Candidate in Metastatic Castration-Resistant Prostate Cancer
Feb 11, 2019
Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer
Dec 20, 2018
Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI® (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer
Sep 24, 2018
Astellas Receives Positive CHMP Opinion for XTANDI® (enzalutamide) for Adult Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer
Aug 22, 2018
Pfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide in Patients with Hormone-Sensitive Prostate Cancer
Jul 13, 2018
U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
May 16, 2018
Astellas Announces Abstracts Highlighting Growing Oncology Portfolio to be Presented at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Mar 19, 2018
U.S. FDA Grants Priority Review for a Supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) in Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
Dec 29, 2017
ANI Pharmaceuticals Acquires Four NDAs from AstraZeneca for $46.5 Million
Sep 14, 2017
Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Trial of XTANDI (enzalutamide) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Aug 31, 2017
Astellas to Present New Data for Enzalutamide and IMAB362 at 2017 European Society of Medical Oncology (ESMO) Annual Meeting
Jun 13, 2017
Prostate Cancer Therapeutics Market Size Worth $12.0 Billion by 2025: Grand View Research, Inc.
Jun 09, 2017
Astellas and Pfizer Announce Amendment to Clinical Research Protocol for Phase 3 PROSPER Trial of enzalutamide in Patients with Non-metastatic Castration-Resistant Prostate Cancer
Latest News
Apr 19, 2024
La Jolla Institute for Immunology and RevolKa started a Research Collaboration
Apr 19, 2024
Two Top Rating Agencies Reaffirm Metropolitan’s Strong Credit Ratings
Apr 19, 2024
Mativ Announces Conference Call to Discuss First Quarter 2024 Results
Apr 19, 2024
LSI Industries Acquires EMI Industries, Expanding Store Fixtures and Food Service Equipment Business
Apr 19, 2024
Anue Water Technologies Adds Four New Channel Partners to Serve Wastewater Treatment Customers in California...
Apr 19, 2024
Kermit Facility Operational Update
Apr 19, 2024
Les Européens cherchent, dans la douleur, des fonds pour leur défense
Apr 19, 2024
Danemark: les forces armées à l'épreuve de leur modernisation
View all News
Agenda
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
21
May
Paris Marriott Rive Gauche & Conference Center
Future Artillery, 21-23 May 2024, Paris Marriott Rive Gauche & Conference Center, France
DELIVERING FIRES IN THE MULTI-DOMAIN BATTLESPACE As artillery reasserts itself as the ‘King of Battlefield’ in the wake...
21
May
United Arab Emirates
ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR Abu Dhabi 2024, 21-23 May 2024, ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR ACCELERATING TRANSFORMATION IN THE NATIONAL SECURITY ECOSYSTEM ISNR Abu Dhabi is the region’s most trusted...
View All Events